A new, generic, non-steroidal anti-inflammatory drug (NSAID) is now available for managing osteoarthritis (OA) pain in horses ...

Enterotoxemia, also called “overeating disease” or “purple gut,” can cause the death of a young calf in as few as 12 hours, with signs that are not detectable ... professional services veterinarian, ...

Please provide your email address to receive an email when new articles are posted on . Avoid a “kitchen sink” work-up, instead focusing on history, findings and imaging. Treatment options ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Patrick Dempsey will begin the VMX conference with his keynote address, sponsored by Boehringer Ingelheim. During the address ... diagnosis and clinical signs. The majority of the session will also ...

Objectives To determine the association between symptoms and signs reported in primary care consultations ... AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, CardioRenal, Cytokinetics, ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

BURLINGTON, ON, Feb. 5, 2025 /CNW/ - Boehringer Ingelheim Canada announces that intravenous and subcutaneous supplies of SPEVIGO ® (spesolimab injection/spesolimab for injection) are now available in ...

Boehringer will leverage ExpressionEdits' Genetic Syntax Engine which generates optimized introns to increase protein expression.

"For patients living with GPP, their flares can be difficult to manage physically and emotionally," said Jensen Yeung, MD, FRCPC, dermatologist in Toronto, Ontario. "As a physician, it has been ...